Latest Breaking News On - Timothyd henry - Page 1 : comparemela.com

Coronary Sinus Reducer an Option for Intractable Angina?

A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number.

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

First Patient Randomized In Askbio Phase II Gene Therapy Trial For Congestive Heart Failure